Hansoh BioMedical R&D Company clinical trials
A subsidiary of Hansoh Pharmaceutical Group Company Limited
The registry lists 47 studies whose lead sponsor is Hansoh BioMedical R&D Company. 43 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 23, 2026.
Registry sponsor names on this page
- Hansoh BioMedical R&D Company47 studies
Something wrong with this grouping? Tell us on the Hansoh Pharmaceutical Group Company Limited page.
Studies
Recruiting first, then most recently updated. Showing 47 of 47. All Hansoh Pharmaceutical Group Company Limited studies →
- A Phase II Study of HS-20093 Injection Combined With Adebrelimab Versus HS-20093 Injection in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic AlterationsRecruitingNCT07824882Phase 2
Sponsor listed in the registry: Hansoh BioMedical R&D Company
- A Phase I Study of HS-20093 in Combination With ZG006 With or Without Adebrelimab in Patients With ES-SCLCNot yet recruitingNCT07892625Phase 1
Sponsor listed in the registry: Hansoh BioMedical R&D Company
- An Open-label Study of HS-20137 in Participants With Moderate-to-Severe Plaque PsoriasisRecruitingNCT07879885Phase 2
Sponsor listed in the registry: Hansoh BioMedical R&D Company
- A Study of HS-20197 in Participants With Advanced Solid TumorsNot yet recruitingNCT07834359Phase 1
Sponsor listed in the registry: Hansoh BioMedical R&D Company
- Phase III Study of HS-20089 With Bevacizumab in Platinum-Sensitive Recurrent Ovarian CancerNot yet recruitingNCT07821606Phase 3
Sponsor listed in the registry: Hansoh BioMedical R&D Company
- HS-20117-2 Injection in Patients With Advanced Solid TumorsRecruitingNCT07775703Phase 1
Sponsor listed in the registry: Hansoh BioMedical R&D Company
- PHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLCRecruitingNCT07645222Phase 1
Sponsor listed in the registry: Hansoh BioMedical R&D Company
- A Phase I Study of HS-20108 in Participants With Advanced Solid TumorsRecruitingNCT06936735Phase 1
Sponsor listed in the registry: Hansoh BioMedical R&D Company
- A Study of HS-20093 in Patients With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)Not yet recruitingNCT07621601Phase 3
Sponsor listed in the registry: Hansoh BioMedical R&D Company
- A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients.RecruitingNCT07283367Phase 1/2
Sponsor listed in the registry: Hansoh BioMedical R&D Company
- A Study of HS-20110 in Participants With Advanced Solid TumorsRecruitingNCT06892379Phase 1
Sponsor listed in the registry: Hansoh BioMedical R&D Company
- A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic AlterationsNot yet recruitingNCT07464327Phase 3
Sponsor listed in the registry: Hansoh BioMedical R&D Company
- HS-20093 in Patients With Advanced Gastric and Gastroesophageal Junction AdenocarcinomaRecruitingNCT07462923Phase 1
Sponsor listed in the registry: Hansoh BioMedical R&D Company
- A Study of HS-20122 in Patients With Advanced Solid TumorsRecruitingNCT06927570Phase 1
Sponsor listed in the registry: Hansoh BioMedical R&D Company
- Evaluation of the Effect of Itraconazole on the Pharmacokinetics of HS-20093 in Patients With Advanced Solid TumorsRecruitingNCT07186452Phase 1
Sponsor listed in the registry: Hansoh BioMedical R&D Company
- HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian CancerRecruitingNCT06855069Phase 3
Sponsor listed in the registry: Hansoh BioMedical R&D Company
- Phase Ib Study of HS-20093+HRS-5041 in Patients With Advanced Prostate CancerRecruitingNCT07115446Phase 1
Sponsor listed in the registry: Hansoh BioMedical R&D Company
- A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung CancerRecruitingNCT06417008Phase 2/3
Sponsor listed in the registry: Hansoh BioMedical R&D Company
- A Study to Evaluate Efficacy and Safety of HS-10374 for Mild-to-moderate Plaque PsoriasisNot yet recruitingNCT06926582Phase 2
Sponsor listed in the registry: Hansoh BioMedical R&D Company
- Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid TumorsRecruitingNCT06621563Phase 1
Sponsor listed in the registry: Hansoh BioMedical R&D Company
- A Study of HS-20137 in Participants with Moderate-to-severe Plaque PsoriasisNot yet recruitingNCT06844799Phase 3
Sponsor listed in the registry: Hansoh BioMedical R&D Company
- ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal CancerRecruitingNCT06825624Phase 1
Sponsor listed in the registry: Hansoh BioMedical R&D Company
- A Study of HS-20124 in Patients with Advanced Solid TumorsRecruitingNCT06763159Phase 1
Sponsor listed in the registry: Hansoh BioMedical R&D Company
- HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid TumorsRecruitingNCT06112704Phase 2
Sponsor listed in the registry: Hansoh BioMedical R&D Company
- ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma.Not yet recruitingNCT06699576Phase 1
Sponsor listed in the registry: Hansoh BioMedical R&D Company
- A Study to Confirm Efficacy and Safety of HS-10374 for Moderate to Severe Plaque PsoriasisNot yet recruitingNCT06672393Phase 3
Sponsor listed in the registry: Hansoh BioMedical R&D Company
- A Study of the Effect and Safety of HS-10390 in the Treatment of Patients with Primary IgA NephropathyNot yet recruitingNCT06635772Phase 2
Sponsor listed in the registry: Hansoh BioMedical R&D Company
- A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy SubjectsRecruitingNCT05942625Phase 1
Sponsor listed in the registry: Hansoh BioMedical R&D Company
- A Study of HS-20106 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic SyndromesNot yet recruitingNCT06594965Phase 2
Sponsor listed in the registry: Hansoh BioMedical R&D Company
- HS-20089 in Patients With Ovarian Cancer and Endometrial CancerRecruitingNCT06014190Phase 2
Sponsor listed in the registry: Hansoh BioMedical R&D Company
- ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other SarcomasRecruitingNCT05830123Phase 2
Sponsor listed in the registry: Hansoh BioMedical R&D Company
- ARTEMIS-006: HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid TumorsRecruitingNCT06007729Phase 2
Sponsor listed in the registry: Hansoh BioMedical R&D Company
- ARTEMIS-003: HS-20093 in Patients With Metastatic Castrate-resistant Prostate Cancer (mCRPC) and Advanced Solid TumorsRecruitingNCT06001255Phase 2
Sponsor listed in the registry: Hansoh BioMedical R&D Company
- A Study of HS-20093 vs Active Surveillance in Limited-Stage Small Cell Lung CancerNot yet recruitingNCT06526624Phase 3
Sponsor listed in the registry: Hansoh BioMedical R&D Company
- Efficacy and Safety of HS-10374 Compared to Placebo in Adults With Active Psoriatic ArthritisRecruitingNCT06176508Phase 2
Sponsor listed in the registry: Hansoh BioMedical R&D Company
- ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid TumorsRecruitingNCT06332170Phase 1
Sponsor listed in the registry: Hansoh BioMedical R&D Company
- HS-20089 Combination Treatment in Subjects With Advanced Solid TumorsRecruitingNCT06336707Phase 1
Sponsor listed in the registry: Hansoh BioMedical R&D Company
- A Study to Find the Best Dose of HS-10384 to Treat Vasomotor Symptoms in Postmenopausal WomenNot yet recruitingNCT06393673Phase 2
Sponsor listed in the registry: Hansoh BioMedical R&D Company
- Study of HS-10384 in Participants of Chinese Postmenopausal WomenRecruitingNCT06122181Phase 1
Sponsor listed in the registry: Hansoh BioMedical R&D Company
- A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum DisordersNot yet recruitingNCT06212245Phase 4
Sponsor listed in the registry: Hansoh BioMedical R&D Company
- A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque PsoriasisRecruitingNCT06077331Phase 2
Sponsor listed in the registry: Hansoh BioMedical R&D Company
- Study of HS-20105 for Injection in Patients With Advanced Solid Tumors.Not yet recruitingNCT06144723Phase 1/2
Sponsor listed in the registry: Hansoh BioMedical R&D Company
- A Phase I Clinical Study of HS-20117 in Participants With Advanced Solid TumorsNot yet recruitingNCT05940116Phase 1
Sponsor listed in the registry: Hansoh BioMedical R&D Company
- Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment FailureCompletedNCT06935409Phase 3
Sponsor listed in the registry: Hansoh BioMedical R&D Company
- ARTEMIS-008:HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung CancerCompletedNCT06498479Phase 3
Sponsor listed in the registry: Hansoh BioMedical R&D Company
- A Drug-Drug Interaction Study Between HS-10374 Tablets and Drospirenone and Ethinyl Estradiol Tablets(Yasmin®)CompletedNCT07181343Phase 1
Sponsor listed in the registry: Hansoh BioMedical R&D Company
- ARTEMIS-007: HS-20093 in Patients With Extensive Stage Small Cell Lung CancerWithdrawnNCT06052423Phase 2
Sponsor listed in the registry: Hansoh BioMedical R&D Company